CV Sciences

CVSI

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$0.02

-0.00 (-1.43%)

Market Cap

$4.1M

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Based on the IPO prospectus (annual filing). This score will refine automatically once the company reports its first quarters.

Share count rising — dilution

+70.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 107.8M (2021) → 184.3M (2025)

CV Sciences makes and sells products derived from hemp, including cannabidiol (CBD). The company has two main parts: a consumer wellness brand that sells CBD oils, capsules, and gummies to everyday shoppers, and a pharmaceutical division working to develop prescription drugs using CBD compounds. Its products reach customers through retail stores, pharmacies, and online channels across the United States.

The company earns most of its revenue from direct product sales in the consumer hemp-CBD market, not from subscriptions or licensing. It operates entirely within the U.S., and with a market cap near zero and a negative operating margin, it is a very small, money-losing business. The CBD supplement market is crowded with hundreds of competitors and lacks strong brand loyalty, which makes it hard for any single company to stand out. The biggest risk CV Sciences faces is simply running out of cash before its pharmaceutical pipeline produces a product that generates meaningful revenue.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-466.7% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$122,000/ year

→ Flat (+3% vs prior year)

0.9% of revenue

Below sector average (18%)

Steady R&D investment year-over-year

Insider Activity

7.8%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$309,000 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

CV Sciences's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

49.0%

Healthy — 49.0% gross margin

Operating Margin

-7.2%

Losing money on operations — -7.2%

ROCE

-29.5%

Weak — -29.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-12.2%

Shrinking sales (-12.2% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-3.7%

Burning cash (-3.7%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

1.29

Elevated debt (1.29)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial